<?xml version="1.0" encoding="UTF-8"?>
<p>The development of new diagnostic platforms can improve molecular methods in terms of speed, sensitivity, and accessibility in the diagnosis of COVID-19. Currently, approximately 11 molecular devices have received urgent approval from the National Administration of Medical Products in China
 <xref rid="B18" ref-type="bibr">
  <sup>18</sup>
 </xref>. In addition, automated RT-PCR systems have been developed, such as the Xpress SARS CoV-2 Test (Cepheid, USA). Using the GeneXpert platform, SARS-CoV-2 E and N2 genes can be detected in approximately 45 minutes. Another innovative alternative is the Abbott ID Now COVID-19 handheld instrument, which detects the SARS-CoV-2 RdRp and N genes. Both Xpress SARS-CoV-2 and Abbott ID Now COVID-19 were authorized for emergency use by the Food and Drug Administration (FDA), USA
 <xref rid="B27" ref-type="bibr">
  <sup>27</sup>
 </xref>
 <sup>,</sup>
 <xref rid="B28" ref-type="bibr">
  <sup>28</sup>
 </xref>.
</p>
